Prophylactic Staphylococcus aureus subunit vaccine shows promising results
22-Dec-2006
"The fact that a vaccine based on our antigen discovery platform has delivered promising data in humans underlines the scientific and commercial potential of Intercell's technology platforms", states Alexander von Gabain, CSO of Intercell. "It is our strategy to develop our own vaccine candidates based on our technologies, and also to partner with the best players in the field to create significant value."
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.